/

Società

Io

Non verificato

Io Therapeutics, Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaMedicina Salute Benessere

5 comunicati stampa

Guarda tutti i comunicati

11/12/2025

Biotecnologia

Medicina Salute Benessere

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).

Fonte

Io Therapeutics, Inc.

Emittente

1.00

0

06/12/2025

Biotecnologia

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

Fonte

Io Therapeutics, Inc.

Emittente

1.00

0

23/12/2024

Biotecnologia

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Fonte

Io Therapeutics, Inc.

Emittente

1.00

0

11/12/2024

Biotecnologia

Medicina Salute Benessere

Annunci Economici

Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor

Fonte

Io Therapeutics, Inc.

Emittente

1.00

0

08/11/2024

Biotecnologia

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers

Fonte

Io Therapeutics, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0